Torley Helen, president and CEO of Halozyme Therapeutics (HALO), has been a consistent seller of company stock. Form 4 filings show 168 total transactions, all in HALO, with zero open-market purchases. The selling has been heavy: total sale value reached $58.1 million, and the 19 most recent sales occurred between September 9 and October 8, 2026.
The pattern is uniform. On each trading day in that window, Helen executed multiple open-market sales (code S) alongside option exercises (code M). For example, on October 8 alone, four sales totaled roughly $2.19 million, paired with an option exercise valued at $368,200. Similar clusters appear on October 6 and 7, with combined daily sales of $2.19 million and $2.23 million respectively. The September transactions follow the same shape: sales of $2.15 million on September 9, $2.14 million on September 10, and $2.14 million on September 11, each matched with a $368,200 option exercise. The per-trade sale values range from about $10,867 to $1.66 million.
The data shows a clear directional bias. Helen has not bought a single share in the period covered. Every transaction is either a sale or an option exercise that immediately precedes a sale. The option exercises are mechanical, and the sales are open-market dispositions. The dollar amounts are substantial, with the largest single sale at $1.66 million on September 11. The absence of any purchases, combined with the consistent selling across multiple dates, indicates a sustained reduction in the CEO's HALO position.
AI-assisted summary